{"id":"NCT01374490","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea","officialTitle":"A Phase 3, Multicenter, Open-Label Evaluation of the Safety and Tolerability of Crofelemer in HIV-Positive Subjects With Diarrhea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06-07","primaryCompletion":"2012-10-31","completion":"2012-10-31","firstPosted":"2011-06-16","resultsPosted":"2020-08-17","lastUpdate":"2020-08-31"},"enrollment":250,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV Enteropathy","Diarrhea With HIV"],"interventions":[{"type":"DRUG","name":"Crofelemer","otherNames":[]}],"arms":[{"label":"Crofelemer","type":"EXPERIMENTAL"}],"summary":"This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive (HIV+) subjects with diarrhea.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).","timeFrame":"48 weeks","effectByArm":[{"arm":"Crofelemer","deltaMin":189,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":250},"commonTop":["Upper respiratory tract infection","Parasitic infection intestinal","Giardiasis","Bronchitis","Constipation"]}}